ClinicalTrials.gg
CompletedNCT07118215Updated Jul 22, 2026

A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin

A Phase 1 interventional study of KarXT and Midazolam in Healthy Volunteers, sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
62
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the effects of KarXT administration on the drug levels of midazolam, fexofenadine, and digoxin in healthy adult participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy volunteer
  • Pharmacokinetics
  • BMS-986510
  • KarXT
  • Cobenfy
  • Midazolam
  • Fexofenadine
  • Digoxin
  • Drug-drug interaction
03

In context

Lead sponsor

Karuna Therapeutics, Inc., a Bristol Myers Squibb company is the lead sponsor of 17 studies on the registry; 8 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.

First submitted after Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be healthy male and female (INOCBP) as determined by no deviation from normal in medical history, physical examination, 12-lead , VS, and clinical laboratory determinations.
  • Participants must have of 18.0 to 32.0 kg/m2.

Exclusion criteria

Exclusion Criteria:

  • Participants must not have organ dysfunction or any deviation from normal in physical examination, VS, , or clinical laboratory determinations beyond what is consistent with the target population reference ranges.
  • Participants must not have cirrhosis, biliary duct abnormalities, hepatobiliary carcinoma, and/or active hepatic viral infections based on the LFT results.
  • Participants must not have any other significant acute or chronic medical illness, as assessed by the investigator.
  • Participants must not have history or high risk of urinary retention, gastric retention, or narrow-angle glaucoma or known history of prostate hypertrophy or nocturia.
  • Participants must not have current or recent (within 3 months of first study intervention administration) GI disease that could possibly affect drug ADME (eg, bariatric procedure).
  • Participants must not have any major surgery, including GI surgery (eg, cholecystectomy and any other GI surgery) that could impact upon the absorption of study intervention (uncomplicated appendectomy and hernia repair are acceptable).
  • Participants must not have history of active GI obstructive disorder.
  • Participants must not have history of bladder stones.
  • Participants must not have history of recurrent urinary tract infections.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Part 1

    Drug: KarXT · Drug: Midazolam

  • Experimental
    Part 2

    Drug: KarXT · Drug: Fexofenadine

  • Experimental
    Part 3

    Drug: KarXT · Drug: Digoxin

  • Experimental
    Part 1a

    Drug: KarXT · Drug: Midazolam

Interventions

  • DrugKarXT

    Drug pages: Xanomeline · Trospium

    Specified dose on specified days

    Also known as: BMS-986510, Xanomeline, Trospium Chloride

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Part 1/1a: Geometric mean ratio (GMR) of Maximum observed plasma concentration (Cmax) of midazolam with and without KarXT

    Time frame: Up to approximately day 24

  2. Part 1/1a: GMR of Area under the plasma concentration-time curve (AUC) of midazolam with and without KarXT

    Time frame: Up to approximately day 24

  3. Part 2: GMR of Cmax of fexofenadine with and without KarXT

    Time frame: Up to approximately day 24

  4. Part 2: GMR of AUC of fexofenadine with and without KarXT

    Time frame: Up to approximately day 24

  5. Part 3: GMR of Cmax of digoxin with and without KarXT

    Time frame: Up to approximately day 24

  6. Part 3: GMR of AUC of digoxin with and without KarXT

    Time frame: Up to approximately day 24

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to approximately day 47

  2. Number of participants with serious adverse events (SAEs)

    Time frame: Up to approximately day 47

  3. Number of participants with physical examination abnormalities

    Time frame: Up to approximately day 24

  4. Number of participants with vital sign abnormalities

    Time frame: Up to approximately day 24

  5. Number of participants with 12-lead electrocardiogram abnormalities (ECGs)

    Time frame: Up to approximately day 24

  6. Number of participants with clinical laboratory assessment abnormalities

    Time frame: Up to approximately day 24

  7. Number of participants with suicidal ideation with the use of the Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Up to approximately day 24

  8. Number of participants with adverse event of special interest (AESIs)

    Time frame: Up to approximately day 47

07

Study locations

1 site
  • Local Institution - 0001
    Lenexa, Kansas 66219-9746, United States
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2025 to primary completion in Jun 2026, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2025
First posted
Aug 12, 2025
StartActual
Sep 29, 2025
Primary completionActual
Jun 25, 2026
CompletionActual
Jun 25, 2026
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07118215
Responsible party
Sponsor
First posted
Aug 12, 2025
Start date
Sep 29, 2025
Primary completion
Jun 25, 2026
Completion
Jun 25, 2026
Last update
Jul 22, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Midazolam · Fexofenadine · Digoxin

Start the discussion